Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 72Neoplasms 7Neoplasm Metastasis 7Breast Diseases 5Neoplasms by Site 3Carcinoma, Intraductal, Noninfiltrating 3Breast Neoplasms, Male 3Ovarian Neoplasms 2Endometrial Neoplasms 2Breast Neoplasm Female 2Advanced Breast Cancer 2Uterine Cervical Neoplasms 1Triple Negative Breast Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Skin Diseases 1Sexual Dysfunctions, Psychological 1Low Grade Serous Ovarian Cancer 1Locoregional Recurrence 1Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer 1Hereditary Sensory and Autonomic Neuropathies 1Head and Neck Neoplasms 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Granulosa Cell Ovarian Cancer 1Fallopian Tube Neoplasms 1Endometrial Stromal Tumors 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Lobular 1Carcinoma, Ductal, Breast 1Breast Carcinoma In Situ 1

Interventions

Anastrozole 2palbociclib 1Tretinoin 1Paclitaxel 1Letrozole 1Fulvestrant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Breast Neoplasm Female × Anastrozole × 1 year × Clear all
NCT03425838 2026-05-20

Endocrine Therapy Plus CDK4/6 in First or Second Line for Hormone (SONIA) Receptor Positive Advanced Breast Cancer

Borstkanker Onderzoek Groep

Phase 3 Active not recruiting
1,050 enrolled
Breast

Breast Neoplasm Female

NCT04113863 2025-12-18

ATRA

Mario Negri Institute for Pharmacological Research

Phase 2 Terminated
76 enrolled
Breast

Breast Neoplasm Female

Data powered by HemOnc (CC BY 4.0) Colophon âš¡